Comparing Treatment With Melatonin to Treatment With Stimulants (Methylphenidate) in Children With Attention Deficit Hyperactivity Disorder and Sleep Difficulties

NCT ID: NCT01393574

Last Updated: 2011-07-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study hypothesis is that some children with Attention-Deficit-Hyperactivity-Disorder (ADHD) who also have sleep onset difficulties will improve with Melatonin treatment to an extent similar to that of stimulants treatment.

In order to check this hypothesis children with a new ADHD diagnosis who also have sleep difficulties will be treated with either Melatonin or with stimulants (Methylphenidate) for one month. The main outcome will be improvement of the ADHD symptoms.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Attention Deficit Hyperactivity Disorder Sleep Onset Insomnia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Melatonin treatment

Treatment with Melatonin before sleep for 1 month - 3 mg for body weight \<40kg, 6mg for body weight \>40kg

Group Type EXPERIMENTAL

Melatonin

Intervention Type DRUG

3 mg for body weight \<40kg, 6 mg for body weight \>40kg, once a day 30-60 minutes before sleep

Stimulants treatment

Treatment with Methylphenidate with a formulary and dose as decided by the treating neurologist, for 1 month.

Group Type ACTIVE_COMPARATOR

Methylphenidate

Intervention Type DRUG

Drug formulary and dose will be decided by the treating neurologist from the available options in Israel (as would be given if not participating in the trial)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Melatonin

3 mg for body weight \<40kg, 6 mg for body weight \>40kg, once a day 30-60 minutes before sleep

Intervention Type DRUG

Methylphenidate

Drug formulary and dose will be decided by the treating neurologist from the available options in Israel (as would be given if not participating in the trial)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ritalin Ritalin SR Ritalin LA Concerta

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* children 6-18 years old with a new ADHD diagnosis who are candidates for treatment with stimulants
* Also they suffer from sleep onset insomnia or difficult awakening

Exclusion Criteria

* Drug treatment for ADHD or for sleep problems in the last 6 months
* Any other chronic medical treatment
* Sleep disorder requiring a different treatment
* Asthma in the last 2 years
Minimum Eligible Age

6 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assaf-Harofeh Medical Center

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Assaf-Harofeh Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Assaf Haroffeh Medical Center

Zeriffin, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Amir Ytzhak, Dr.

Role: CONTACT

972-8-9779944

Amir Livne, Dr.

Role: CONTACT

972-8-9779944

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

83/11

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Procedural Learning in Participants With ADHD
NCT00446537 UNKNOWN EARLY_PHASE1
Treating Sleep in Teens With ADHD
NCT04270812 COMPLETED NA